Si-Yang Wang
Research Subjects
Si-Yang Wang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Xu
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China
11 shared publications - Fan Zhang
Fifth Affiliated Hospital of Sun Yat-sen University 10 Zhuhai
11 shared publications - Haojiang Li
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
11 shared publications - Hui Chen
Chia Tai Tian Qing Pharmaceutical Group 8
11 shared publications - Ji-Bin Li
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
11 shared publications - Jian-Ming Gao
Sun Yat-sen University Cancer Center 2 Guangzhou
11 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S1 shows percentage change from baseline in target lesion size over time for individual patients in the TP cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S1 shows percentage change from baseline in target lesion size over time for individual patients in the TP cohort.